COPD drug Daxas fails to obtain FDA panel's endorsement

04/7/2010 | Google · Reuters

An FDA panel voted 10-5 against recommending the approval of Daxas, Nycomed and Forest Laboratories' drug for chronic obstructive pulmonary disease, citing the product's dangerous side effects. A Forest official said the drugmaker is "disappointed" by the vote but thinks the committee's concerns "are clearly negotiable with the agency."

View Full Article in:

Google · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Abbott
Menlo Park, CA
Sales Manager, Employer Programs
PartnerRe Health